Lineage Cell Therapeutics Inc (AMEX:LCTX)
$ 0.52 -0.0926 (-15.12%) Market Cap: 135.03 Mil Enterprise Value: 105.07 Mil PE Ratio: 0 PB Ratio: 1.75 GF Score: 63/100

Lineage Cell Therapeutics, Inc. - Special Call Transcript

Nov 17, 2020 / 09:00PM GMT
Release Date Price: $1.4 (+6.06%)
Brian M. Culley
Lineage Cell Therapeutics, Inc. - CEO, President & Director

Hello, and welcome, everybody, to today's call. My name is Brian Culley, and I'm the CEO at Lineage Cell Therapeutics. I'd like to thank you for joining today and learning more about the exciting work we're doing in cell therapy, and more specifically, our allogeneic cell transplant technology, which we believe can lead to clinical outcomes which are out of the reach of traditional therapeutic approaches.

The reason for our call today is that thanks to an unexpected surge of 4 patients being treated in just 8 days, we recently completed enrollment of all 24 patients in a Phase I/IIa clinical trial and felt this is a great time to provide a more fulsome update.

Before I introduce our therapeutic expert today, we have a lot of new followers, and I want to ensure that everyone is starting from the same baseline. So I'm going to present just 5 slides to remind you about our, work and then I will introduce Dr. Riemann, who will be able to do a deep dive into the data which we have generated to date.

So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot